RxDoctor Payments Data

Grigor Varlakov, MD

Family Medicine · Spring Hill, FLNPI 1083812994

Payments from drug & device makers

$2,400in general payments, 2019–2025

Across 59 payments — averaging $40.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$483
  • Amgen$431
  • Lilly USA, LLC$297
  • Amarin Pharma, Inc.$285
  • Novo Nordisk$210
  • Boehringer Ingelheim$144
  • plus $550 from 10 others

What the payments were for

  • Food & beverage$2,38599%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,400 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$6,827
Medicare patients
25
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide16$15,278
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,782
Dabigatran EtexilateDabigatran Etexilate Mesylate18$7,637
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl18$6,654
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$5,855
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$4,574
Atorvastatin Calcium175$3,256
Pregabalin42$3,065
Levothyroxine Sodium127$2,287
Gabapentin60$2,144
Tamsulosin Hcl73$2,085
Rosuvastatin Calcium81$2,044
Duloxetine Hcl19$2,009
Albuterol Sulfate HfaAlbuterol Sulfate56$1,953
Lisinopril146$1,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$297$15,27816 claims
GSKTrelegy Ellipta$483$7,78212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Spring Hill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →